Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
Miyake H, Matsumoto R, Fujimoto K, Mizokami A, Uemura H, Kamoto T, Kawakami S, Nakamura K, Maekawa S, Shibayama K, Watanabe A, Ito M, Tajima Y, Matsuyama H, Uemura H. Miyake H, et al. Among authors: shibayama k. Eur Urol Oncol. 2024 Jun;7(3):625-632. doi: 10.1016/j.euo.2023.12.013. Epub 2024 Jan 30. Eur Urol Oncol. 2024. PMID: 38296736 Free article.
Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study.
Uemura H, Satoh T, Tsumura H, Arai G, Imanaka K, Shibayama K, Fujii K, Rooney B, Lopez-Gitlitz A, Espina B, Perez-Ruixo C, Small EJ, Smith M. Uemura H, et al. Among authors: shibayama k. Prostate Int. 2020 Dec;8(4):190-197. doi: 10.1016/j.prnil.2020.05.002. Epub 2020 May 28. Prostate Int. 2020. PMID: 33425798 Free PMC article.
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.
Suzuki H, Shin T, Fukasawa S, Hashine K, Kitani S, Ohtake N, Shibayama K, Tran N, Mundle S, Fizazi K, Matsubara N. Suzuki H, et al. Among authors: shibayama k. Jpn J Clin Oncol. 2020 Jul 9;50(7):810-820. doi: 10.1093/jjco/hyaa030. Jpn J Clin Oncol. 2020. PMID: 32188988 Free PMC article. Clinical Trial.
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study.
Okusaka T, Ikeda M, Fukutomi A, Kobayashi Y, Shibayama K, Takubo T, Gansert J. Okusaka T, et al. Among authors: shibayama k. Jpn J Clin Oncol. 2014 May;44(5):442-7. doi: 10.1093/jjco/hyu034. Jpn J Clin Oncol. 2014. PMID: 24782485 Clinical Trial.
Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors.
Murakami H, Doi T, Yamamoto N, Watanabe J, Boku N, Fuse N, Yoshino T, Ohtsu A, Otani S, Shibayama K, Takubo T, Loh E. Murakami H, et al. Among authors: shibayama k. Cancer Chemother Pharmacol. 2012 Sep;70(3):407-14. doi: 10.1007/s00280-012-1924-9. Epub 2012 Jul 19. Cancer Chemother Pharmacol. 2012. PMID: 22810805 Free PMC article. Clinical Trial.
The epidemiology of pulmonary Mycobacterium abscessus species in Japanese population.
Ihara H, Kondo K, Muto Y, Haba M, Nakazawa H, Handoh T, Arai Y, Shibayama K, Sumiyoshi I, Ochi Y, Watanabe J, Takei S, Nakamura A, Fujimoto Y, Togo S, Takahashi K. Ihara H, et al. Among authors: shibayama k. J Infect Chemother. 2024 Mar 1:S1341-321X(24)00053-9. doi: 10.1016/j.jiac.2024.02.018. Online ahead of print. J Infect Chemother. 2024. PMID: 38432559
411 results